Asset Details
Do you wish to reserve the book?
The clinical effects and mechanism of action of ranibizumab in treating myopic choroidal neovascularization
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The clinical effects and mechanism of action of ranibizumab in treating myopic choroidal neovascularization
Do you wish to request the book?
The clinical effects and mechanism of action of ranibizumab in treating myopic choroidal neovascularization
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The clinical effects and mechanism of action of ranibizumab in treating myopic choroidal neovascularization
2025
Overview
Purpose
Myopic choroidal neovascularization (CNV) is a common reason for visual impairment. This study investigated the clinical effects of repeated intravitreal injections of ranibizumab among patients with CNV secondary to pathologic myopia.
Methods
This study involved a single-center, non-randomized clinical prospective cohort research design including 39 patients with myopic CNV and a control group of 10 patients with cataract. Plasma and aqueous humor samples were analyzed to compare cytokine concentrations between the two groups and assess changes after intravitreal ranibizumab injections. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were also monitored.
Results
BCVA values and CMT varied significantly after intravitreal ranibizumab injections. The study group had significantly higher plasma concentrations of vascular endothelial growth factor (VEGF)-A and significantly lower epidermal growth factor (EGF) and angiopoietin-2 concentrations than the control group. Likewise, in the aqueous humor, the study group had significantly higher concentrations of fibroblast growth factor and significantly lower concentrations of EGF and VEGF-A than the control group. The average VEGF-A content decreased significantly after 1 and 2 months relative to the baseline. Mean VEGF-D and endoglin contents at two months were significantly reduced compared to the baseline and at 1 month. The average EGF contents were significantly higher at 2 months than the baseline.
Conclusion
Ranibizumab could increase the BCVA and lower the CMT and cytokines involved in angiogenesis. This study contributes to further understanding the pathogenesis of myopic CNV and promoting new drug research and development for patients with this condition.
Publisher
Springer Netherlands,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Angiogenesis Inhibitors - administration & dosage
/ Choroidal Neovascularization - diagnosis
/ Choroidal Neovascularization - drug therapy
/ Choroidal Neovascularization - etiology
/ Choroidal Neovascularization - metabolism
/ Endoglin
/ Female
/ Humans
/ Male
/ Medicine
/ Myopia
/ Myopia, Degenerative - complications
/ Myopia, Degenerative - diagnosis
/ Myopia, Degenerative - drug therapy
/ Patients
/ R&D
/ Ranibizumab - administration & dosage
/ Tomography, Optical Coherence
/ Vascular endothelial growth factor
